What is HC Wainwright’s Forecast for APRE FY2024 Earnings?

Aprea Therapeutics, Inc. (NASDAQ:APRE) – Equities research analysts at HC Wainwright upped their FY2024 earnings per share estimates for Aprea Therapeutics in a research note issued on Monday, November 18th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($2.39) for the year, up from their previous forecast of ($2.41). HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Aprea Therapeutics’ current full-year earnings is ($2.56) per share. HC Wainwright also issued estimates for Aprea Therapeutics’ Q4 2024 earnings at ($0.54) EPS, FY2025 earnings at ($0.95) EPS, FY2026 earnings at ($0.86) EPS and FY2027 earnings at ($0.61) EPS.

Separately, Wedbush restated an “outperform” rating and issued a $11.00 target price on shares of Aprea Therapeutics in a research note on Tuesday, August 13th.

Aprea Therapeutics Price Performance

Shares of APRE stock opened at $3.02 on Wednesday. The stock’s fifty day simple moving average is $3.33 and its 200 day simple moving average is $3.86. Aprea Therapeutics has a one year low of $2.15 and a one year high of $8.85. The firm has a market cap of $16.41 million, a price-to-earnings ratio of -1.07 and a beta of 0.97.

Aprea Therapeutics (NASDAQ:APRE) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.11. Aprea Therapeutics had a negative net margin of 1,029.50% and a negative return on equity of 57.86%. The business had revenue of $0.35 million during the quarter, compared to analysts’ expectations of $0.45 million.

Insider Transactions at Aprea Therapeutics

In related news, Director Marc Duey acquired 30,000 shares of the stock in a transaction on Wednesday, October 16th. The stock was purchased at an average price of $4.39 per share, for a total transaction of $131,700.00. Following the transaction, the director now owns 240,113 shares of the company’s stock, valued at $1,054,096.07. The trade was a 14.28 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bernd R. Seizinger bought 10,000 shares of the company’s stock in a transaction on Friday, October 11th. The stock was bought at an average cost of $2.68 per share, with a total value of $26,800.00. Following the completion of the purchase, the director now owns 44,730 shares of the company’s stock, valued at approximately $119,876.40. The trade was a 28.79 % increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 42,290 shares of company stock valued at $165,096 in the last three months. 12.80% of the stock is owned by corporate insiders.

Institutional Trading of Aprea Therapeutics

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Stonepine Capital Management LLC acquired a new stake in Aprea Therapeutics, Inc. (NASDAQ:APRE) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 137,174 shares of the company’s stock, valued at approximately $558,000. Aprea Therapeutics accounts for 0.5% of Stonepine Capital Management LLC’s holdings, making the stock its 21st largest holding. Stonepine Capital Management LLC owned approximately 2.53% of Aprea Therapeutics as of its most recent SEC filing. 34.19% of the stock is currently owned by institutional investors and hedge funds.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.